August 2026 Biopharma Hedge Fund Stock Picks: MIRM and 2 More
- Aug 19
- 3 min read
Updated: Aug 24
For August 2026, BPIQ’s Hedge Fund Stock Picks highlight three biopharma companies with distinct catalyst and risk profiles: Mirum Pharmaceuticals, 2nd pick and the 3rd pick.
MIRM combines a growing commercial rare-disease franchise with several near-term regulatory and late-stage clinical catalysts, giving it the strongest fundamental floor of the three. The second pick offers a late-stage psoriasis program supported by positive Phase 3 results, along with a higher-risk Phase 2 lupus readout. The third pick has the lowest near-term catalyst risk and a substantial cash position, but its retained cardiology pipeline remains earlier in clinical development.
All three rank among the most widely held biopharma stocks in BPIQ’s latest hedge fund holdings, indicating strong interest from specialized healthcare investors. Hedge fund ownership does not guarantee that a stock will be a good investment, but it can provide a powerful starting point for identifying companies worthy of further attention and diligence.
MIRM: The Commercial Rare-Liver Pick
Mirum Pharmaceuticals has the lowest long-term fundamental risk of the August 2026 BPIQ AI picks. Its approved rare-liver franchise and diversified late-stage pipeline make it less dependent on any one upcoming event than the other two names.
The company has:
11 BPIQ-tracked hedge fund holders, the highest count among the three August picks.
Q2 2026 product sales of $176.2 million and $561 million in cash and investments, supporting its commercial base and profitability potential.
A September 26, 2026 PDUFA for zilurgisertib in FOP, followed by AZURE-1 Phase 3 topline in chronic HDV in Q3 and EXPAND Phase 3 plus AZURE-4 results in Q4 2026.
An approved LIVMARLI franchise and multiple pipeline programs, so no one catalyst represents the entire enterprise-value story.
MIRM remains near-term catalyst-heavy. The PDUFA and pivotal studies must succeed amid competitive FOP, HDV, and cholestatic markets. Its commercial scale, however, makes each event a smaller share of value than the other stock picks this month.
Bottom line: MIRM may appeal to investors looking for a commercially supported rare-disease company with the lowest long-term risk profile of the three, while accepting substantial 2026 catalyst activity.
See What a Detailed BPIQ Investor Report Includes
The section above provides only a brief overview of MIRM. BPIQ Pro, Elite & APEX members receive the complete MIRM investor report, including its investment thesis, upcoming catalysts, clinical data, competitive landscape, financial position, valuation, and key risks.
To show what these reports include, we are providing a previous BPIQ investor report on another company as a free sample:
This sample report reflects the information available at the time of its original publication. It is provided to demonstrate the format and depth of BPIQ’s detailed investor reports.
Want All 3 August 2026 Biopharma Hedge Fund Stock Picks?
As a special gift, this free article reveals MIRM as one of BPIQ’s August 2026 stock picks. BPIQ Elite and APEX members receive all three picks, along with detailed investor reports for each company.
Upgrade to Elite or Apex to receive:
All 3 August 2026 BPIQ Hedge Fund Stock Picks
The complete MIRM investor report
Detailed reports for all 3 companies
Access to the BPIQ AI Stock Picker
See the BPIQ AI Stock Picker in Action
Built on more than 20 years of biopharma investing experience, the BPIQ AI Stock Picker combines BPIQ data, hedge fund holdings, and AI-powered analysis. It turns your catalyst, company-size, and risk preferences into one focused stock idea for further diligence.
Final Takeaway
The August 2026 BPIQ Hedge Fund Stock Picks provide three distinct biopharma profiles.
MIRM has the strongest commercial downside floor and the lowest long-term risk. Second pick offers a validated psoriasis asset and potentially greater long-term upside, but it also carries a concentrated SLE binary, commercial risk, and a finite cash runway Third pick has less 2026 binary-event risk than MIRM or the second pick, but its retained cardiac programs carry more long-term development risk.
All three have meaningful hedge fund sponsorship and important upcoming milestones. Their differences are useful to help you identify which of these high quality biopharma smid-cap companies are most interesting for your further diligence
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 8/19/26 RF, EJV
Comments